Paperpal Prime Logo

Cancer Biotherapy and Radiopharmaceuticals : Impact Factor & More

eISSN: 1557-8852pISSN: 1084-9785

Key Metrics

CiteScore
5.2
H-Index
66
Impact Factor
< 5
SJR
Q2Oncology
SNIP
0.71
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Cancer Biotherapy and Radiopharmaceuticals

Cancer Biotherapy and Radiopharmaceuticals Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher MARY ANN LIEBERT, INC
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1996
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Cancer Biotherapy and Radiopharmaceuticals ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Cancer Biotherapy and Radiopharmaceuticals

Cavitation-Free Acoustic Sensitization Enhances PLK4-Targeted Therapy Using the Phillyrin Derivative DE02 in Osteosarcoma.
  • 1 Sep 2026
  • Cancer biotherapy & radiopharmaceuticals
Lactylation Signatures as Predictors of Prognosis and Therapeutic Response in Lung Adenocarcinoma: Implications for Ultrasound-Based Therapeutic Strategies.
  • 1 Sep 2026
  • Cancer biotherapy & radiopharmaceuticals
Radiopharmaceutical Oncology Care Supported by Ultrasound-Guided Superior Vena Cava-Right Atrial Junction Port Tip Positioning in Adult Cancer Patients.
  • 1 Aug 2026
  • Cancer biotherapy & radiopharmaceuticals
Impact of Nurse-Coordinated Care on Outcomes of Ultrasound-Assisted Radiopharmaceutical Cancer Therapy.
  • 1 Aug 2026
  • Cancer biotherapy & radiopharmaceuticals
Prospective Clinical Assessment of Ultrasound-Assisted Radiopharmaceutical Imaging Under Anesthesia for Oncologic Evaluation.
  • 1 Aug 2026
  • Cancer biotherapy & radiopharmaceuticals
Prognostic Factor Analysis and Nomogram Development in Castration-Resistant Prostate Cancer with Visceral Metastases for Future Radionuclide Therapy Selection.
  • 29 Jul 2026
  • Cancer biotherapy & radiopharmaceuticals
Cavitation-Free Acoustic Sensitization Enhances PLK4-Targeted Therapy Using the Phillyrin Derivative DE02 in Osteosarcoma.
  • 1 Sep 2026
  • Cancer biotherapy & radiopharmaceuticals
Lactylation Signatures as Predictors of Prognosis and Therapeutic Response in Lung Adenocarcinoma: Implications for Ultrasound-Based Therapeutic Strategies.
  • 1 Sep 2026
  • Cancer biotherapy & radiopharmaceuticals
Radiopharmaceutical Oncology Care Supported by Ultrasound-Guided Superior Vena Cava-Right Atrial Junction Port Tip Positioning in Adult Cancer Patients.
  • 1 Aug 2026
  • Cancer biotherapy & radiopharmaceuticals
Impact of Nurse-Coordinated Care on Outcomes of Ultrasound-Assisted Radiopharmaceutical Cancer Therapy.
  • 1 Aug 2026
  • Cancer biotherapy & radiopharmaceuticals
Prospective Clinical Assessment of Ultrasound-Assisted Radiopharmaceutical Imaging Under Anesthesia for Oncologic Evaluation.
  • 1 Aug 2026
  • Cancer biotherapy & radiopharmaceuticals
Prognostic Factor Analysis and Nomogram Development in Castration-Resistant Prostate Cancer with Visceral Metastases for Future Radionuclide Therapy Selection.
  • 29 Jul 2026
  • Cancer biotherapy & radiopharmaceuticals

FAQs on Cancer Biotherapy and Radiopharmaceuticals